CJC-1295
The GHRH analogue that extends growth-hormone release for days
Definition
CJC-1295 is a synthetic 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH) that stimulates endogenous pulsatile secretion of growth hormone (GH) and, secondarily, IGF-1. The version with DAC (Drug Affinity Complex) binds covalently to serum albumin, extending its half-life to 6-8 days. The version without DAC has a short half-life (~30 min) and is typically combined with Ipamorelin for synergy through two independent pathways.
Detailed explanation
CJC-1295 acts on the pituitary, stimulating natural GH release without saturating receptors or suppressing the hypothalamic-pituitary axis — unlike exogenous GH, which causes negative regulation. The preserved physiological pulsatility is the key to its superior safety profile.
The CJC-1295 (without DAC, 100 mcg) + Ipamorelin (200 mcg) combination is the most-used stack: CJC raises the GH set point via the GHRH pathway and Ipamorelin amplifies pulses via the ghrelin pathway. Administered subcutaneously 1-2 times daily (before sleep and optionally fasting), 5 days a week, in cycles of 8-12 weeks.
Documented effects from studies and clinical practice: IGF-1 increase 50-100%, improved body composition (more lean mass, less visceral fat), accelerated post-exercise recovery, improved deep sleep (N3 phase stimulation), tissue regeneration, and mild libido increase.
Monitoring should include IGF-1, fasting glucose, HOMA-IR, and, in long cycles, ApoB. Contraindicated in active cancer or history of GH/IGF-1 dependent neoplasms.
Scientific sources
Interested in related treatments?
Generate My Protocol